NFKB1 and atherosclerosis: In recent years, with the development of relevant studies, more and more evidence has shown that PPARγ can enhance the cholesterol efflux efficiency through positively regulating PPARγ/LXRα/ABCA1-ABCG1 pathway and can also inhibit endothelial cell inflammation via negatively regulating PPARγ/NF-κB p65 pathway, which is one of the important potential targets for the treatment of atherosclerosis [31, 32].